Amgen Inc Investor Conference Call from American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting Transcript
My name is Erica, and I will be your conference facilitator today for Amgen's conference call from the American Academy of Allergy, Asthma & Immunology Annual Meeting. (Operator Instructions) I will now introduce Arvind Sood, Vice President of Investor Relations. Mr. Sood, you may begin.
Thank you, Erica. Good morning, and good afternoon, everybody. Thanks for joining us. So earlier this morning, we presented important data in a poster forum on tezepelumab, and this was presented at the American Academy of Asthma, Allergy and Immunology Meeting. This data is from our Phase III NAVIGATOR study evaluating tezepelumab in severe asthma patients.
To review this data in additional detail, I'm joined this morning by Dr. David Reese, our Executive Vice President of Research and Development; as well as 2 of our clinical investigators who Dave will introduce and who can provide a broader perspective on how they see tezepelumab fitting within the armamentarium of therapies to treat severe asthmatic patients. Dave will make a
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
